

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **June 2021**

Commission File Number: **001-40065**

**IM Cannabis Corp.**

(Exact Name of Registrant as Specified in Charter)

**Kibbutz Gilil Yam, Central District, Israel 4690500**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F [ ] Form 40-F [ x ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IM CANNABIS CORP.**  
(Registrant)

Date: June 8, 2021

By: /s/ Oren Shuster  
Oren Shuster  
Title: Chief Executive Officer and Director

---

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
<a href="#">99.1</a>	<a href="#">News Release dated June 7, 2021</a>
<a href="#">99.2</a>	<a href="#">Form 7 – Monthly Progress Report dated June 7, 2021</a>

---



IM Cannabis Announces Supply Agreement with Canadian LP The Flowr Corporation; Plan to Import Ultra-Premium Products as part of Enhanced Portfolio to Meet Growing Israeli Demand

**Toronto, Canada; Gili Yam, Israel - June 7, 2021** - IM Cannabis Corp. (the "Company" or "IMC") (CSE: IMCC, NASDAQ: IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Israel, Germany and Canada, is pleased to announce that Focus Medical Herbs Ltd. ("Focus Medical") has signed a multi-year supply agreement with The Flowr Corporation ("Flowr") (TSX.V: FLWR, OTC: FLWPF), a Canadian licensed producer of ultra-premium adult-use recreational and medical cannabis products.

Under the terms of the three-year supply agreement (the "Supply Agreement"), and subject to fulfilling applicable regulatory and import requirements, Focus Medical will import Flowr's ultra-premium cannabis strains into Israel. The first shipment is expected to be available in the Israeli market in H2, 2021. Flowr is an established leader in Canada's premium dry flower market. This new partnership with Flowr strengthens and further contributes to IMC's new indoor ultra-premium product category under the IMC brand.

**Oren Shuster, Chief Executive Officer of IMC** commented, "We have been strategically focused on securing a strong pipeline of premium indoor cannabis from Canada to enhance our IMC-branded portfolio with a new category of high-quality THC products. We are pleased to partner with Flowr, one of Canada's leading cannabis producers, to bring their premium strains to Israeli consumers and expand our medical cannabis offerings to meet the needs of patients. Partnerships and collaborations with premium suppliers, such as Flowr, are foundational to IMC's growth strategy. We will continue to execute on our premium product strategy and grow our global network of strategic partners, keeping the patient at the heart of our work as we forge a new path in the Israeli cannabis market."

#### **About IM Cannabis Corp.**

IMC is an MCO in the medical and adult-use recreational cannabis sector, headquartered in Israel and with operations in Israel, Germany and Canada. Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its business to offer intellectual property-related services to the medical cannabis industry.

In Europe, IMC operates through Adjupharm GmbH ("Adjupharm"), a German-based subsidiary and EU GMP-certified medical cannabis processor and distributor. IMC's European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.

In Canada, IMC operates through Trichome JWC Acquisition Corp. ("JWC"). JWC is a licensed producer located in Kitchener, Ontario, selling cannabis flower, pre-rolls, hash and kief in the Canadian recreational cannabis market under the JWC and Wagners brands. JWC operates with high standards for providing clean, consistent, aeroponically-grown premium cannabis products to medical patients and the adult-use market throughout Canada and the world. On March 31, 2021, IMC entered into a definitive agreement to acquire MYM Nutraceuticals Inc. ("MYM") and its licensed producer subsidiary, Highland Grow Inc. This transaction, if completed, will reinforce IMC's goal of being a leading global premium cannabis producer and purveyor.

---

## About Focus Medical Herbs Ltd.

Focus Medical is one of eight original licensed producers of medical cannabis in Israel and has over 10 years of experience growing high quality medical cannabis in the Israeli market. Focus Medical is an "investee" of the Company under IFRS due to the Company's "de facto control" over Focus Medical despite not having any direct or indirect ownership of it. Focus Medical has an exclusive commercial agreement with IMC to distribute its production under the IMC brand. In addition to its own capacity, Focus Medical has signed supply agreements with other cultivators for additional supply using its proprietary genetics and for sale under the IMC brand.

## About The Flowr Corporation

The Flowr Corporation is a Toronto-headquartered cannabis company with operations in Canada and Europe. Its Canadian operating campus, located in Kelowna, BC, includes a purpose-built, GMP-designed indoor cultivation facility; an outdoor and greenhouse cultivation site; and a state-of-the-art R&D facility. From this campus, Flowr produces recreational and medicinal products. Internationally, Flowr intends to service the global medical cannabis market through its subsidiary Holigen Holdings Limited, which has a license for cannabis cultivation in Portugal and operates a GMP licensed facility in Portugal. In 2020, Flowr's BC Pink Kush was recognized as the top indica strain in Canada by KIND magazine.

Flowr aims to support improving outcomes through responsible cannabis use and, as an established expert in cannabis cultivation, strives to be the brand of choice for consumers and patients seeking the highest-quality craftsmanship and product consistency across a portfolio of differentiated cannabis products.

For more information, please visit [flowrcorp.com](http://flowrcorp.com) or follow Flowr on Twitter: @FlowrCanada and LinkedIn: The Flowr Corporation.

## Disclaimer for Forward-Looking Statements

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "**forward-looking information**"). Forward-looking information are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements relating to the Supply Agreement, the Company's product portfolio, including a new line of high-quality THC products, the ability of the Company to continue to execute on its premium product strategy and growing its global network of strategic partners, the completion of the acquisition of MYM and the Company's business and strategic plans.

Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to the ability of the Company to execute its business plan, the continued growth of the medical and/or recreational cannabis markets in the countries in which the Company operates or intends to operate, the Company maintaining "de facto" control over Focus Medical in accordance with IFRS 10, Focus Medical maintaining its existing Israeli medical cannabis propagation and cultivation licenses and the expected decriminalization and/or legalization of adult-use recreational cannabis in Israel. The Company considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those expressed or implied in the forward-looking information. Such risks include, without limitation: the ability of IMC to complete the acquisition of MYM pursuant to a plan of arrangement under the *Business Corporations Act* (British Columbia) (the "Transaction") on the terms contemplated by the definitive agreement entered into on April 1, 2021 and including the receipt, in a timely manner, of all the regulatory, court, securityholder, stock exchange and other third-party approvals necessary to consummate the Transaction; the Company's inability to capture the benefits associated with its acquisition of Trichome Financial Inc.; unexpected disruptions to the operations and businesses of the Company and/or Focus Medical as a result of the COVID-19 global pandemic or other disease outbreaks including a resurgence in the cases of COVID-19; the Israeli government deciding to delay or abandon the decriminalization and/or legalization of adult-use recreational cannabis; any bill relating to the decriminalization and/or legalization of adult-use recreational cannabis in Israel being rejected by Israeli parliament; any change in the political environment which would negatively affect the decriminalization and/or legalization of adult-use recreational cannabis in Israel; engaging in activities considered illegal under United States federal law; the ability of the Company to comply with applicable government regulations in a highly regulated industry; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture or use of medical cannabis in Israel, Germany, or any other foreign jurisdictions in which the Company intends to operate; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture or use of adult-use recreational cannabis in Canada; any failure of the Company to maintain "de facto" control over Focus Medical in accordance with IFRS 10; the Company and Focus Medical having to rely on third party cannabis producers to supply the Adjupharm and Focus Medical with product to successfully fulfill previously announced sales agreements and purchase commitments; the ability of Focus Medical and Adjupharm to deliver on their sales commitments; the risk that regulatory authorities in Israel may view the Company as the deemed owner of more than 5% of Focus Medical in contravention to Israeli rules restricting the ownership of Israeli cannabis cultivators and thereby jeopardizing Focus Medical's cannabis propagation or cultivation licenses; any unexpected failure of Focus Medical to renew its propagation or cultivation licenses with the Israeli Ministry of Health; any unexpected failure of Focus Medical to maintain any of its commercial facilities or land lease agreements; any unexpected failure of Adjupharm to renew its production, wholesale, narcotics handling or import/export licenses, permits, certificates or approvals; the Company's reliance on management; the lack of merger and acquisition opportunities; inconsistent public opinion and perception regarding the use of cannabis; perceived effects of medical cannabis products; the Company's ability to maintain or improve the brand position of the IMC brand in Israel's medical cannabis market; political instability and conflict in the Middle East; adverse market conditions; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; costs of inputs; crop failures; litigation; currency fluctuations; competition; industry consolidation; failure to meet NASDAQ's continued listing requirements; and loss of key management and/or employees.

---

**For more information:**

Oren Shuster  
Chief Executive Officer  
+972-77-3603504  
[info@imcannabis.com](mailto:info@imcannabis.com)

Elizabeth Barker  
Investor Relations  
KCSA Strategic Communications  
+1 212 896 1203  
[ebarker@kcsa.com](mailto:ebarker@kcsa.com)

Caitlin Kasunich  
Media Relations  
KCSA Strategic Communications  
[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)  
+1 212.896.1241

Gal Wilder  
Media Relations  
+1 416-602-4092  
[gal.wilder@cohnwolfe.ca](mailto:gal.wilder@cohnwolfe.ca)

---

---

FORM 7

**MONTHLY PROGRESS REPORT**

Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC").

Trading Symbol: IMCC

Number of Outstanding Listed Securities as of 31/05/2021:

57,067,651 Common Shares, 7,374,363 Warrants

Date: June 7, 2021

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
    - **On May 4, 2021 the Issuer announced the commencement of an overnight marketed offering (the "Offering") of the Issuer's common shares (each an "Offered Share") and common share purchase warrants (each a "2021 Warrant") on a best-efforts agency basis. The 2021 Warrants would be issued to purchasers of Offered Shares for no additional consideration and would entitle the holder to purchase common shares of the Issuer at a price and for a term to be determined in the context of marketing for the Offering. The Offering would be conducted pursuant to the Issuer's effective shelf registration statement on Form F-10 filed with the U.S. Securities and Exchange Commission (the "SEC") and the corresponding Canadian base shelf prospectus filed with the securities regulatory authority in each of the provinces and territories of Canada.**
    - **On May 5, 2021, the Issuer announced the terms of the Offering and the filing of a final prospectus supplement with Canadian regulatory authorities and the SEC. The securities offered under the Offering would be issued and sold in the United States and in the Canadian provinces of British Columbia, Ontario and Alberta in accordance with applicable securities laws. The Issuer indicated its intention to use the net proceeds of the Offering for: (i) supporting growth initiatives in core markets of Israel, Germany and Canada; (ii) additional strategic mergers and acquisitions opportunities; and (iii) general working capital purposes. The Offering would contemplate the sale and issuance of up to 6,086,956 Offered Shares at a price of US\$5.75 per Offered Share for aggregate gross proceeds of up to approximately US\$35 million. The Issuer would also issue up to 3,043,478 2021 Warrants to purchasers of Offered Shares, for no additional consideration, with each 2021 Warrant entitling the holder to purchase one common share of the Issuer at an exercise price of US\$7.20 for a term of 5 years from the closing date of the Offering (the "Closing Date"). Pursuant to the terms of the Offering, the Agent (as defined below) was granted an over-allotment option to purchase up to an additional 913,044 Offered Shares and 456,522 2021 Warrants on the same terms and conditions for a period of 30 days following the Closing Date.**
-

- On May 7, 2021, the Issuer closed the Offering. A total of 6,086,956 Offered Shares at a price of US\$5.75 per Offered Share were sold and issued for aggregate gross proceeds of US\$34,999,997.00. The Issuer also issued 3,043,478 2021 Warrants to purchasers of Offered Shares, for no additional consideration, that each entitle the holder to purchase one common share of the Issuer at an exercise price of US\$7.20 for a term of 5 years from the Closing Date.
- On May 17, 2021, the Issuer filed its interim financial statements and MD&A for the three months ended March 31, 2021, and announced its unaudited financial results for Q1 2021.
- On May 30, 2021, the Issuer completed the first closing of its previously announced transaction with Panaxia Pharmaceutical Industries Israel Ltd. and Panaxia Logistics Ltd., part of the Panaxia Labs Israel, Ltd. group of companies ("Panaxia") involving the Issuer's acquisition of Panaxia's trading house and in-house pharmacy activities (the "Panaxia Transaction"). As part of the first closing, all online-related activities and related intellectual property were transferred to the Issuer.

2. Provide a general overview and discussion of the activities of management.

**Management of the Issuer ("Management") is focused on continuing the Issuer's growth in all three markets in which it currently operates: Israel, Germany and Canada. Management is focused on increasing the Issuer's presence in Canada by executing its merger & acquisition strategy and seeking to acquire additional licensed cannabis producers, including its proposed acquisition of MYM Nutraceuticals Inc., with the objective of becoming a dominant supplier in the premium and super premium segment of the Canadian recreational cannabis market. Management is also focused on identifying new strategic investments and growth opportunities in Israel and Europe, including, but not limited to, securing additional supply and distribution agreements in Germany and the rest of Europe, and additional sales and supply agreements in Israel through Focus Medical Herbs Ltd. ("Focus Medical").**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

---

**Pursuant to the first closing of the Panaxia Transaction, the Issuer now operates: (1) an online pharmacy business under the name *Panaxia to the Home*" offering home-delivery of medical cannabis products in Israel; and (2) a customer service centre**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not Applicable.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**On May 5, 2021, in connection with the Offering, the Issuer entered into an agency agreement (the "Agency Agreement") with Roth Canada, ULC (the "Agent") appointing the Agent as the Issuer's sole and exclusive agent, and to effect the sale of the securities offered under the Offering (the "Offered Securities") on a best efforts basis. Among other contractual and business arrangements set forth in the Agency Agreement, the Issuer granted the Agent a 30-day over-allotment option, commencing on the Closing Date, to purchase such number of additional Offered Securities as is equal to 15% of the number of Offered Securities issued under the Offering, solely to cover over-allotments, if any, and for market stabilization purposes, as applicable. The Agent is not a Related Person of the Issuer.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not Applicable.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**On May 30, 2021, the Issuer completed the first closing of the Panaxia Transaction that transferred all online-related activities and related intellectual property of Panaxia to the Issuer, including, but not limited to, the online sales platform for medical cannabis products operating under the name "*Panaxia to the Home*", call centre operations, a CRM platform and the lease of a large storage facility to support the operations of *Panaxia to the Home*". Pursuant to the first closing of the Panaxia Transaction, the Issuer paid approximately \$2,162,162 as cash consideration for the above-mentioned assets. Following such closing and subject to the fulfilment of a post-closing obligation pursuant to the terms of the Panaxia Transaction, an additional \$772,200 will be paid in cash to Panaxia. Panaxia is not a related party to the Issuer.**

---

8. Describe the acquisition of new customers or loss of customers.

**Not Applicable.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

- **On May 21, 2021, the European Union Intellectual Property Office approved the registration of the Issuer's "IMC" logo as a trademark, valid until November 11, 2030.**
- **On May 30, 2021, as part of the first closing of the Panaxia Transaction, the Issuer received exclusive rights to use certain intellectual property of Panaxia on the terms set forth under the Panaxia Transaction, including the right to use the "*Panaxia to the Home*" (in Hebrew: *Panaxia Ad Habait*) name and the active customer website running on the URL address <https://stock.panaxia.store/stock/>.**
- **As part of the Issuer's acquisition of Trichome Financial Corp. ("Trichome") and its wholly-owned subsidiary Trichome JWC Acquisition Corp. ("TJAC"), which closed on March 18, 2021 (the "Trichome Acquisition"), the Issuer engaged external valuers to complete a preliminary Purchase Price Allocation ("PPA") report as part of the financial reporting requirements for the quarter-ended March 31, 2021. The preliminary PPA report was completed by the external valuers during the month. For more information, please see the Issuer's financial statements for the quarter-ended March 31, 2021 posted on SEDAR.**

**The PPA is a requirement for accounting purposes under IFRS 3 - *Business Combinations*. Through completing the PPA, a portion of the purchase consideration in the Trichome Acquisition was assigned to identified intangible assets which include cultivation licenses as well as customer relationships. The PPA report is preliminary in nature and is unaudited, meaning there could be material changes to the values assigned to the identified intangible assets acquired by the Issuer and there could be changes in the actual intangible assets identified in the Trichome Acquisition.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

---



**Not Applicable.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not Applicable.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not Applicable.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**On May 17, 2021, TJAC entered into a revolving credit facility (the "Facility") with a private Canadian creditor for a total commitment of up to \$5 million. The Facility matures in 12 months and bears interest at the higher of (i) 9.75% per annum; and (ii) the Toronto Dominion Bank Prime Rate, as set by the Toronto-Dominion Bank, plus 7.30% per annum. The Facility was guaranteed by Trichome. The term of the Facility may be extended for up to two additional periods of 180 days each upon mutual agreement.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common Shares	6,086,956	Pursuant to the Offering. Please refer to Section 1 above for more information.	US\$34,999,997.00 to be used as stated under Section 1 above.
	1,300	Exercise of 5,200 warrants	\$6,760.00 to be used for working capital.
	4,018	Exercise of stock options	\$6,428.80 to be used for working capital.
Common Share purchase warrants	3,043,478	Pursuant to the Offering. Please refer to Section 1 above for more information.	Not Applicable.
Agent Warrants	182,609	Pursuant to the Offering as compensation for agent services. Each Agent Warrant is exercisable for one common share at an exercise price of US\$6.61 at any time following November 5, 2021 until November 5, 2024.	Not Applicable.
Incentive Stock Options	1,471,465	Each incentive stock option granted on May 19, 2021 is exercisable for one common share at an exercise price of \$5.87 for a period of five years from the grant date.	Not Applicable.
Restricted Share Units	550,000	Each restricted share unit granted on May 19, 2021 is exercisable for one common share, according to the vesting schedule, under which 33.3% will vest on July 23, 2021 and the remaining 66.7% will vest on a quarterly basis over 8 quarters as of July 23, 2021.	Not Applicable

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**Not Applicable.**

16. Provide details of any changes in directors, officers or committee members.

**Not Applicable.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The current global uncertainty with respect to the spread of COVID-19, the rapidly evolving nature of the pandemic and local and international developments related thereto and its effect on the broader global economy and capital markets may impact the Issuer's business in the coming months.**

**The Issuer has taken proactive measures to protect the health and safety of its employees in order to continue delivering high quality medical cannabis products to its patients and to maintain its financial health. The Issuer has postponed planned investments in certain jurisdictions until global economic risks subside, but it continues to focus on its acquisition strategy in North America and Europe. The Issuer also continues to develop the IMC brand by increasing physician awareness and engagement to drive sales of IMC-branded medical cannabis products in Germany and by seeking new supply and sales agreements in Israel.**

---

While the precise impact of the COVID-19 outbreak on the Issuer remains unknown, the rapid spread of COVID-19 and declaration of the outbreak as a global pandemic have resulted in travel advisories and restrictions, certain restrictions on business operations, social distancing precautions and restrictions on group gatherings which could have negative impact on businesses around the world, including the cannabis markets in which the Issuer and its subsidiaries and related companies operate. Such implications may also affect Trichome's debtors, including their respective abilities to repay their obligations. The spread of COVID-19 may also have a material adverse effect on global economic activity and could result in volatility and disruption to global supply chains and the financial and capital markets. These disruptions could cause interruptions in supplies and other services from third parties upon which the Issuer relies; decrease demand for products; and cause staff shortages, reduced customer traffic, and increased government regulation, all of which may materially and negatively impact the business, financial condition and results of operations of the Issuer, its subsidiaries and Focus Medical.

---

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 7, 2021

Oren Shuster

Name of Director or Senior Officer

"Oren Shuster"

Signature

Chief Executive Officer

Official Capacity

<b>Issuer Details</b> Name of Issuer IM Cannabis Corp.	For Month End May 2021	Date of Report YY/MM/D 2021/06/07
Issuer Address 550 Burrard Street, Suite 2300, Bentall 5		
City/Province/Postal Code Vancouver, BC V6C 2B5	Issuer Fax No. ( )	Issuer Telephone No. +972 546687515
Contact Name Yael Harrosh	Contact Position General Counsel and Business Manager	Contact Telephone No. +972 546687515
Contact Email Address <a href="mailto:yael.h@imcannabis.com">yael.h@imcannabis.com</a>	Web Site Address <a href="http://www.imcannabis.com/">http://www.imcannabis.com/</a>	